Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. - Wikidata - wikimedia - TriplyDB

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

http://www.wikidata.org/entity/Q35175584

about

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy Recent advances in bone-targeted therapies of metastatic prostate cancer Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.Acrometastasis as the Initial Presentation of a KRAS-Positive Colon Cancer Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice.Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Measurement of Ototoxicity Following Intracochlear Bisphosphonate Delivery Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Skeletal metastasis: treatments, mouse models, and the Wnt signaling.An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.Plant-derived anticancer agents: a promising treatment for bone metastasis.Genes, molecules and patients--emerging topics to guide clinical pain research.Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.Bisphosphonates and cancer: what opportunities from nanotechnology?In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis.Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer.

P2860

Q26824762-38145E6E-0B9D-4952-BE39-12B66BB0E06A Q27004011-7D8DC1BA-72DA-400F-AFC5-97971C1B58D0 Q33703763-6C5919A5-A059-40DD-A632-7605A1569EA7 Q34122791-73319BEF-CA49-44FE-913C-1F05D7C2ACD3 Q34273676-56FE5FAC-4FAF-41E6-9442-FB684F6ADE07 Q34381979-9D8AFAE9-6BC4-41E4-BF86-6BB25DCCABF4 Q34617864-8B7D1CBC-C0D3-4193-AB6F-2DB5E5CF909F Q34779663-8F3C128D-62F5-4FC4-84A7-C4BEB5203821 Q35740351-72034573-E14B-4B13-BCBE-B4C103A4007E Q35855513-242DCFCD-F74F-42E2-A207-7182C2E6E3F6 Q36131779-D26320E5-9965-4782-913B-DD2C413D34AC Q36433566-444AA9C0-928D-4DCD-8894-D3C0C344D565 Q36478792-31654443-D24C-4AB3-BFB1-DD89E1838F01 Q36491479-DEDE9B0B-23D7-4B83-B6CE-0ADDD257D3F0 Q36612034-C2617D4F-69D0-424D-8C1E-BE963F4CB260 Q36945036-A20D8A7C-9D0A-43FB-BA24-25D3AE10946D Q36946864-13EFCFA9-67F9-4185-B046-66E015A572C7 Q37004194-D602AA85-D0F7-45D7-A1D9-6C0E0085AC8A Q37274132-BB0D2F88-C2D8-4040-90EC-8B7659FDB3EF Q37354085-A84101B3-5FFD-476B-B7E2-8EBBDF80653B Q37486791-3BFC6598-4282-4F7A-9179-7AEFB574E1CA Q37640924-F7FA1760-F9BD-4FAF-814B-DE9A86A93803 Q38090292-1E4831F8-90AB-47FC-80A2-C4C0B63915B9 Q38754093-B3A628A2-583E-4C01-B374-9541688F6CB8 Q39942547-4FB19C57-8C44-4E21-A268-BDD2EB8AB684 Q41162635-7EB548B0-8621-42EC-8C7A-7D0F3C5EF6FE Q41595578-A534941D-8404-4055-A86E-7E7997A4AB7C Q41829362-3191EC55-26B7-475E-9C71-F6943C78A7B7 Q43057295-004DE37A-BA43-4FBE-A5E8-764D5A79A628 Q47145765-35971B19-702E-4DCA-9A19-695C164B589B Q47559000-D54C8A0C-D026-47F7-BD09-7651AF22D1DE Q55030407-D22BFDF4-EC85-4A76-8409-00B139F08208

P2860

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

http://www.wikidata.org/entity/Q35175584

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Approval summary for zoledroni ...... ma and cancer bone metastases.

@ast

Approval summary for zoledroni ...... ma and cancer bone metastases.

@en

type

label

Approval summary for zoledroni ...... ma and cancer bone metastases.

@ast

Approval summary for zoledroni ...... ma and cancer bone metastases.

@en

prefLabel

Approval summary for zoledroni ...... ma and cancer bone metastases.

@ast

Approval summary for zoledroni ...... ma and cancer bone metastases.

@en

P1433

Q35175584-2CB95ABE-750F-4AE5-9201-7D4D569DC74B

P1476

Q35175584-60837441-C921-46D2-952A-5113D4321D2A

P2093

Q35175584-1FF6F8E5-1C75-45BC-A654-AE037E788056

Q35175584-27676F3E-4E66-41E4-9F43-172FCA5E1FB0

Q35175584-2A9D6751-C043-437F-B67C-9FB7FB606E19

Q35175584-39671043-4194-4901-A4E5-3DD0F05F06E6

Q35175584-4F239BE5-0074-40A0-9022-DB033E4DF4A3

Q35175584-4FB7DB01-EEA0-49FC-9E3B-6C9971C2F168

Q35175584-5CB40EFA-4E7E-4AFB-9762-5B4228AB5B6B

Q35175584-7538D6D1-C0DD-40A0-B6DD-751EBE8C1226

Q35175584-8C5E9B35-E10F-4EC1-BBF9-4B41AD726014

Q35175584-9B589B79-D256-42C6-99FA-96F8F0CE5E7A

P304

Q35175584-5647664F-B2AD-444B-B9A2-60D79EAF85C2

P31

Q35175584-76C3A4B0-47C6-42B6-A5B9-A2ED5C7FB10D

P407

Q35175584-754FC0B7-DF8D-4561-90AB-05E38136B0C5

P433

Q35175584-44754986-ECC2-47AE-90AE-A7C2CA21FBA1

P478

Q35175584-6B8A09A8-E687-42C4-A24E-886570E340B9

P577

Q35175584-80F912EF-D381-4E57-A716-FE8D25467250

P698

Q35175584-9C3ED22D-3D8E-4587-BEF4-094F2AADA181

P1433

Clinical Cancer Research

P1476

Approval summary for zoledroni ...... oma and cancer bone metastases

@en

P2093

Amna Ibrahim

http://www.w3.org/2001/XMLSchema#string

Atiqur Rahman

http://www.w3.org/2001/XMLSchema#string

Brian Booth

http://www.w3.org/2001/XMLSchema#string

Debra Vause

http://www.w3.org/2001/XMLSchema#string

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Grant Williams

http://www.w3.org/2001/XMLSchema#string

Jogarao V S Gobburu

http://www.w3.org/2001/XMLSchema#string

John Leighton

http://www.w3.org/2001/XMLSchema#string

Nancy Scher

http://www.w3.org/2001/XMLSchema#string

Ning Li

http://www.w3.org/2001/XMLSchema#string

P304

2394-2399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12855610

http://www.w3.org/2001/XMLSchema#string